Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XEDS | ISIN: US2697961082 | Ticker-Symbol: 1E6
Tradegate
27.03.24
19:16 Uhr
4,640 Euro
+0,020
+0,43 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
EAGLE PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
EAGLE PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,6004,68015:05
4,5804,68015:00

Aktuelle News zur EAGLE PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.03.EAGLE PHARMACEUTICALS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4051
11.03.Eagle Pharmaceuticals announces resignation of Brian Cahill as CFO1
08.03.EAGLE PHARMACEUTICALS, INC. - 8-K, Current Report2
29.02.Eagle Pharmaceuticals announces workforce reduction3
29.02.Eagle Pharmaceuticals to cut 36% of workforce3
29.02.EAGLE PHARMACEUTICALS, INC. - 8-K, Current Report1
13.02.EAGLE PHARMACEUTICALS, INC. - 8-K, Current Report2
18.01.Eagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio171WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today provided an update on its bendamustine intellectual property portfolio....
► Artikel lesen
17.01.EGRX Investor Update: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline288Kaplan Fox & Kilsheimer LLP EGRX Investor Update: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline 17-Jan-2024 / 06:23...
► Artikel lesen
16.01.EAGLE PHARMACEUTICALS, INC. - 8-K, Current Report2
15.12.23EAGLE PHARMACEUTICALS, INC. - 8-K, Current Report4
08.12.23Eagle Pharmaceuticals faces legal probe over delayed quarterly report, CEO exit7
06.12.23EAGLE PHARMACEUTICALS, INC. - 8-K, Current Report1
06.12.23Eagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City3
29.11.23Why Is Eagle Pharmaceuticals Stock Trading Lower Today?6
29.11.23Eagle Pharmaceuticals falls after disclosing non-compliance with Nasdaq rule3
29.11.23Eagle Pharmaceuticals says Scott Tarriff has retired as CEO3
29.11.23Eagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q158WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the "Company") today announced that it received a notice (the "Notice") on November 27, 2023 from...
► Artikel lesen
29.11.23Eagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Announces Management Change189- CEO and Founder Scott Tarriff Retires - - Chairman Michael Graves to Serve as Interim Executive Chairman - WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc....
► Artikel lesen
29.11.23EAGLE PHARMACEUTICALS, INC. - 8-K, Current Report1
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1